NEW YORK, November 27, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), WellPoint Inc. (NYSE: WLP), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Forest Laboratories Inc. (NYSE: FRX), and Envision Healthcare Holdings, Inc. (NYSE: EVHC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Gilead Sciences Inc. Research Report
On November 22, 2013, Gilead Sciences, Inc. (Gilead) announced that Sovaldi, its investigational once-daily oral nucleotide analogue polymerase inhibitor, has received supportive opinion from the Medicinal Products for Human Use (CHMP), to be approved for the treatment of chronic hepatitis C virus (HCV) infection in adults in combination with other agents. According to the Company, the CHMP's recommendation will now be reviewed by the European Commission for approval, and if approved, Sovaldi could be available in the EU in Q1 2014. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
WellPoint Inc. Research Report
On November 11, 2013, WellPoint Inc. (WellPoint) announced that it has been recognized as one of the 2014 Top 100 Military Friendly Employer® by Victory Media, publisher of G.I. Jobs and Military Spouse. The Company informed that it has achieved 74th position on the list and that it has made into the list for the fifth year. Karin Sarratt, Vice President of Talent Management and Chief Diversity Officer at WellPoint said, "Being named to the list of Top Military Friendly Employers for the last five years acknowledges the significant efforts that WellPoint has dedicated to establishing and improving best practices for recruiting and retaining veterans. We know that veterans and our associates serving in the National Guard and Reserve bring tremendous value to our organization; their contributions and commitment make us stronger as a company so we can succeed at transforming healthcare with trusted and caring solutions." The Full Research Report on WellPoint Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Questcor Pharmaceuticals, Inc. Research Report
On November 22, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that the Company has been recognized with an "Everyday Hero" award by the NephCure Foundation. According to the Company, the award marks its 'tireless efforts' to advance science and research in the field of nephrology as well as to promote educational efforts related to the treatment of proteinuria in patients with kidney disease who are suffering from nephrotic syndrome. Steve Cartt, Chief Operating Officer of Questcor, said, "Questcor is honored to have received this recognition from NephCure. We feel strongly about supporting research and educational initiatives that will positively impact patients with kidney disease and the nephrology community as a whole. Our flagship product, Acthar, is an FDA-approved prescription medication that is used by an increasing number of nephrologists to induce remission of proteinuria in patients who are suffering from certain types of nephrotic syndrome. We are proud to support the nephrology community through the funding of research, education and other important initiatives." The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Forest Laboratories Inc. Research Report
On November 21, 2013, Forest Laboratories, Inc. (Forest Laboratories) and Gedeon Richter Plc. (Gedeon Richter) jointly announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter in relation to the New Drug Application (NDA) for cariprazine, an atypical antipsychotic for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. According to the Company, FDA in its letter has acknowledged that cariprazine clearly demonstrated effectiveness in the treatment of schizophrenia and mania associated with bipolar disorder. However, the Agency indicated more information, including additional clinical trial data, would be needed. Dr. Marco Taglietti, President, Forest Research Institute, said, "The unmet medical need for schizophrenia and bipolar disorder remains high. We are committed to pursuing novel treatment options like cariprazine to address patient needs. Forest and Gedeon Richter plan to meet with the FDA in the very near future to discuss the complete response letter and define a path forward." The Full Research Report on Forest Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Envision Healthcare Holdings, Inc. Research Report
On November 13, 2013, Envision Healthcare Holdings Inc. (EVHC) and Envision Healthcare Corporation (Envision Corporation) (both together, Envision Healthcare) announced three new appointments. The Company informed that it has appointed Mark V. Mactas to the Boards of Directors of EVHC as well as Envision Corporation and will serve as a member of the Compliance and Compensation Committees. Envision Healthcare also announced the appointment of Nicholas A. Poan as Chief Accounting Officer and Controller, effective immediately, and that of William Huron as the Company's Chief Compliance Officer. The Full Research Report on Envision Healthcare Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved